SG11202010011RA - Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs - Google Patents

Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs

Info

Publication number
SG11202010011RA
SG11202010011RA SG11202010011RA SG11202010011RA SG11202010011RA SG 11202010011R A SG11202010011R A SG 11202010011RA SG 11202010011R A SG11202010011R A SG 11202010011RA SG 11202010011R A SG11202010011R A SG 11202010011RA SG 11202010011R A SG11202010011R A SG 11202010011RA
Authority
SG
Singapore
Prior art keywords
antibodies
bispecific constructs
bispecific
constructs
Prior art date
Application number
SG11202010011RA
Inventor
Tibor Keler
Joel Goldstein
Laura A Vitale
Lizhen He
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of SG11202010011RA publication Critical patent/SG11202010011RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202010011RA 2018-04-17 2019-04-17 Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs SG11202010011RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658899P 2018-04-17 2018-04-17
US201962826091P 2019-03-29 2019-03-29
PCT/US2019/027897 WO2019204462A2 (en) 2018-04-17 2019-04-17 Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs

Publications (1)

Publication Number Publication Date
SG11202010011RA true SG11202010011RA (en) 2020-11-27

Family

ID=66429586

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010011RA SG11202010011RA (en) 2018-04-17 2019-04-17 Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs

Country Status (12)

Country Link
US (4) US11459393B2 (en)
EP (1) EP3781265A2 (en)
JP (2) JP7466459B2 (en)
KR (1) KR20210011919A (en)
CN (1) CN112292185A (en)
AU (1) AU2019256383A1 (en)
BR (1) BR112020021271A2 (en)
CA (1) CA3097369A1 (en)
IL (1) IL277968A (en)
MX (1) MX2020010913A (en)
SG (1) SG11202010011RA (en)
WO (1) WO2019204462A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101958753B1 (en) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human cd27 and uses thereof
JP7466459B2 (en) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド Anti-CD27 and Anti-PD-L1 Antibodies and Bispecific Constructs
KR20220071264A (en) * 2019-09-30 2022-05-31 하버 바이오메드 (상하이) 컴퍼니 리미티드 Anti-PD-L1 antigen binding protein and applications thereof
WO2021226984A1 (en) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody against pd-1 and pd-l1
CN112430271B (en) * 2020-11-13 2021-09-03 武汉滨会生物科技股份有限公司 Bispecific single-chain antibody and application
CN116917322A (en) * 2021-02-19 2023-10-20 沙裴隆有限公司 Bispecific single domain antibodies against PD-L1 and CD47 and uses thereof
AU2022253269A1 (en) 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023218046A1 (en) * 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023224412A1 (en) * 2022-05-19 2023-11-23 (주)샤페론 Bispecific humanized single domain antibody to pd-l1 and cd47, and use thereof

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc HEPATITIS B YTANTIGEN FRAMSTAELLD MED REKOMBINANT-DNA-TEKNIK, VACCIN, DIAGNOSTISKT MEDEL OCH CELLINJER SAMT FOERFARANDEN FOER FRAMSTAELLNING DAERAV.
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990006951A1 (en) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ATE159031T1 (en) 1989-07-25 1997-10-15 Smithkline Biolog ANTIGENS AND METHODS FOR THE PRODUCTION THEREOF
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
CA2087272C (en) 1990-07-13 2005-10-11 Brian Seed Cd53 cell surface antigen and use thereof
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ES2366201T3 (en) 1994-07-15 2011-10-18 University Of Iowa Research Foundation IMMUNMODULATING OLIGONUCLEOTIDES.
US5955087A (en) 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6010853A (en) 1997-05-29 2000-01-04 Dana-Farber Cancer Institute Siva genes, novel genes involved in CD27-mediated apoptosis
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6787638B1 (en) 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
US20080213778A1 (en) 1998-12-30 2008-09-04 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
WO2000041508A2 (en) 1999-01-15 2000-07-20 Mount Sinai School Of Medicine Of The City University Of New York Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
US20030035790A1 (en) 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
HU228477B1 (en) 1999-08-23 2013-03-28 Dana Farber Cancer Inst Inc Pd-1, a receptor for b7-4, and uses therefor
PL362804A1 (en) 1999-08-23 2004-11-02 Dana-Farber Cancer Institute Novel b7-4 molecules and uses therefor
US6808192B1 (en) 1999-11-24 2004-10-26 The Holland Group, Inc. Trailing arm suspension
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
CA2392477A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
EP1303299B1 (en) 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
AU2001275285A1 (en) 2000-06-06 2001-12-17 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
JP2005507635A (en) 2001-02-12 2005-03-24 メダレックス， インク． Human monoclonal antibody against Fcα receptor (CD89)
MXPA03008959A (en) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, a receptor for b7-4, and uses therefor.
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
US6787688B2 (en) 2001-07-06 2004-09-07 Harmos Music, Ltd. Musical instrument
EP1446416A4 (en) 2001-11-19 2005-11-30 Applied Molecular Evolution Tumor specific monoclonal antibodies
US7115716B2 (en) 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
WO2003068268A2 (en) 2002-02-14 2003-08-21 Bioinvent International Ab Treatment, diagnosis and imaging of disease
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
DK2206517T3 (en) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
CA2516128A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
AU2004213452A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic GPCR targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7194710B2 (en) 2004-03-23 2007-03-20 Fujitsu Limited Scheduling events in a boolean satisfiability (SAT) solver
AU2005295038B2 (en) 2004-10-06 2012-05-17 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
JP5252635B2 (en) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド Human monoclonal antibody against programmed death ligand 1 (PD-L1)
US20080213267A1 (en) 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP2889309B1 (en) 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of pd-1 or pd-l1
WO2007102200A1 (en) 2006-03-07 2007-09-13 Osaka University Anti-cd20 monoclonal antibody
WO2007124361A2 (en) 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
US7851581B2 (en) 2006-08-22 2010-12-14 Momentive Performance Materials Inc. Film forming composition with spreading properties
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
SI2079760T1 (en) 2006-12-27 2016-11-30 Emory University Compositions and methods for the treatment of infections
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
PT2222697E (en) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
WO2009061996A2 (en) 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
EP2090320A1 (en) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
US9023999B2 (en) 2008-06-30 2015-05-05 Kyowa Hakko Kirin Co., Ltd Anti-CD27 antibody
PT2352759T (en) 2008-07-16 2018-01-08 Inst Res Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
BRPI0917891A2 (en) 2008-08-25 2015-11-24 Amplimmune Inc pd-1 antagonists and methods of using them
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
MX338825B (en) 2008-10-02 2016-05-03 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins.
JP5520961B2 (en) 2008-11-28 2014-06-11 エモリー ユニバーシティ Methods for treating infections and tumors
WO2010080463A1 (en) 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
WO2011031833A2 (en) 2009-09-09 2011-03-17 Theraclone Sciences, Inc. Human anti-cancer antibodies
WO2011060218A1 (en) 2009-11-13 2011-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulated programmed death ligand-1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
PT2504364T (en) 2009-11-24 2017-11-14 Medimmune Ltd Targeted binding agents against b7-h1
CA2791383C (en) 2010-03-05 2022-09-20 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
KR101958753B1 (en) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human cd27 and uses thereof
US20120213771A1 (en) * 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
EP2591001B1 (en) 2010-07-09 2021-11-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to cd27
US20120021377A1 (en) 2010-07-26 2012-01-26 Chun-Leon Chen Electric implant torque wrench
CA2814780C (en) 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
KR20140002649A (en) 2010-10-27 2014-01-08 베이롤 칼리지 오브 메드신 Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc Half immunoglobulin binding proteins and uses thereof
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
CN103796680A (en) 2011-06-21 2014-05-14 约翰霍普金斯大学 Focused radiation for augmenting immune-based therapies against neoplasms
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
MY175224A (en) 2012-03-15 2020-06-16 Janssen Biotech Inc Human anti-cd27 antibodies, methods, and uses
US20140079691A1 (en) 2012-09-20 2014-03-20 Anaptysbio, Inc. Thermostable antibody framework regions
SG11201505330QA (en) 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2015000059A1 (en) 2013-07-03 2015-01-08 University Health Network Antibodies to toso
JP2016531907A (en) 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Combination of CD27 agonist and immune checkpoint inhibition for immune stimulation
CA2921639A1 (en) 2013-09-05 2015-03-12 Aduro Biotech Holdings, Europe B.V. Cd70-binding peptides and method, process and use relating thereto
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
JP6613304B2 (en) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Anti-CD276 antibody (B7H3)
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
EP3245231B1 (en) 2015-01-16 2020-08-12 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
EP3285804A1 (en) 2015-04-23 2018-02-28 Medimmune Limited Combination therapy for non-small cell lung cancer positive for egfr mutation
EP3978521A1 (en) 2015-05-22 2022-04-06 Huahui Health Ltd. Anti-pre-s1 hbv antibodies
WO2016210129A1 (en) 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CA2990620A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
CN106699888B (en) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 PD-1 antibody and preparation method and application thereof
JP6631072B2 (en) 2015-07-31 2020-01-15 富士通株式会社 Biological simulation system and biological simulation method
EP3370769A4 (en) 2015-11-03 2019-05-22 Janssen Biotech, Inc. Antibodies specifically binding tim-3 and their uses
CN106939047B (en) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 PD-L1 antibody and preparation method thereof
CN109071665B (en) 2016-04-18 2022-11-01 塞德斯医疗公司 Agonistic antibodies that bind human CD40 and uses thereof
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
JOP20190055A1 (en) * 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
AU2017367734A1 (en) 2016-12-01 2019-06-20 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
CA3055127A1 (en) 2017-03-09 2018-09-13 Genmab A/S Antibodies against pd-l1
IL269209B2 (en) 2017-04-01 2023-11-01 Avm Biotechnology Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
US20200071417A1 (en) 2017-04-19 2020-03-05 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
MX2019014268A (en) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy.
JP7466459B2 (en) * 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド Anti-CD27 and Anti-PD-L1 Antibodies and Bispecific Constructs
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy

Also Published As

Publication number Publication date
US20210198374A1 (en) 2021-07-01
US11459393B2 (en) 2022-10-04
US20200109207A1 (en) 2020-04-09
EP3781265A2 (en) 2021-02-24
WO2019204462A3 (en) 2019-12-26
WO2019204462A2 (en) 2019-10-24
AU2019256383A1 (en) 2020-11-26
US11332537B2 (en) 2022-05-17
US20220025063A1 (en) 2022-01-27
BR112020021271A2 (en) 2021-01-26
CA3097369A1 (en) 2019-10-24
KR20210011919A (en) 2021-02-02
MX2020010913A (en) 2021-01-08
JP2024056862A (en) 2024-04-23
JP2021521793A (en) 2021-08-30
CN112292185A (en) 2021-01-29
IL277968A (en) 2020-11-30
JP7466459B2 (en) 2024-04-12
US20220324990A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
IL277968A (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
IL289946A (en) Bispecific antibodies against cd3 and cd20
IL283530A (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
IL279053A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use
IL279974A (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
IL279455A (en) Anti-pd-1 antibodies and uses thereof
HK1255465A1 (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
ZA201906457B (en) Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL278772A (en) Anti-ox40 antibodies and methods of use
IL274564A (en) Anti-pd-l1 antibody and il-7 fusions
IL268051A (en) Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
ZA202006255B (en) Anti-pd-l1 antibody and use thereof
IL269645A (en) Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3833693A4 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
IL280757A (en) Monoclonal antibodies against human tim-3
IL278862A (en) Monospecific and multispecifc anti-tmeff2 antibodies and their uses
IL276675A (en) Anti-pd-1 antibodies and uses thereof
ZA202003858B (en) Monoclonal antibodies and methods for using same
IL285569A (en) Anti-pd-l1 antibody and use thereof
IL283180A (en) Anti-pd-1 antibodies and uses thereof
GB201910138D0 (en) Anti-pd-l1 antibodies
ZA202004784B (en) Humanized and de-immunized antibodies
ZA201906513B (en) Anti-pd-l1 antibody and use thereof